Close
Company Search
Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Astrazeneca (AZN) Share Price

Price 11,196.00p on 27-03-2025 at 17:31:46
Change -36.00p -0.32%
Buy 11,198.00p
Sell 11,194.00p
Buy / Sell AZN Shares
Add to Watchlist
Add to Portfolio
Add to Quickpicks
Last Trade: Sell 4,815.00 at 11,196.00p
Day's Volume: 1,524,995
Last Close: 11,196.00p
Open: 11,168.00p
ISIN: GB0009895292
Day's Range 11,114.00p - 11,242.00p
52wk Range: 9,670.00p - 13,338.00p
Market Capitalisation: £173,554m
VWAP: 11,192.3104p
Shares in Issue: 1,550m

Sector: Medicine and Biotech

Listed In: FTSE All-Share, FTSE All-Share ex Investment Trusts, FTSE Lower Yield, FTSE 350 ex Investment Trusts, FTSE 350 , FTSE 100,

Astrazeneca (AZN) Latest Trades

Buy/Sell Volume Trade Prc Trade Type Trade Time
Sell* 4,815 11,196.00p SI Trade
Suspected SELL Trade
 17:23:24 - 27-Mar-25
Sell* 1,602 11,196.00p SI Trade
Suspected SELL Trade
 17:23:23 - 27-Mar-25
Sell* 3,990 11,196.00p SI Trade
Suspected SELL Trade
 17:22:16 - 27-Mar-25
Sell* 4,711 11,196.00p SI Trade
Suspected SELL Trade
 17:22:16 - 27-Mar-25
Sell* 150 11,196.00p SI Trade
Suspected SELL Trade
 17:22:16 - 27-Mar-25
Sell* 112 11,196.00p SI Trade
Suspected SELL Trade
 17:22:16 - 27-Mar-25
Sell* 246 11,196.00p SI Trade
Suspected SELL Trade
 17:22:16 - 27-Mar-25
Sell* 3,160 11,196.00p SI Trade
Suspected SELL Trade
 17:22:16 - 27-Mar-25
Sell* 3,108 11,196.00p SI Trade
Suspected SELL Trade
 17:22:16 - 27-Mar-25
Buy* 5,412 11,205.561p SI Trade
Negotiated Trade
 16:47:01 - 27-Mar-25
See more Astrazeneca trades

Astrazeneca (AZN) Share Price History

Time period:
to
Date Open High Low Close Volume
27th Mar 2025 (Thu) 11,168.00 11,242.00 11,114.00 11,196.00 1,524,995
26th Mar 2025 (Wed) 11,298.00 11,348.00 11,126.00 11,232.00 1,735,898
25th Mar 2025 (Tue) 11,452.00 11,576.00 11,316.00 11,316.00 2,722,353
24th Mar 2025 (Mon) 11,608.00 11,630.00 11,334.00 11,452.00 973,247
21st Mar 2025 (Fri) 11,826.00 11,826.00 11,608.00 11,608.00 3,858,529
20th Mar 2025 (Thu) 11,728.00 11,876.00 11,728.00 11,808.00 1,506,643
19th Mar 2025 (Wed) 11,798.00 11,910.00 11,776.00 11,784.00 1,410,570
18th Mar 2025 (Tue) 11,908.00 11,976.00 11,810.00 11,846.00 1,483,480
17th Mar 2025 (Mon) 12,090.00 12,090.00 11,784.00 11,904.00 1,670,169
14th Mar 2025 (Fri) 11,860.00 12,018.00 11,854.00 11,994.00 2,288,804
13th Mar 2025 (Thu) 11,706.00 11,898.00 11,644.00 11,882.00 2,893,371
12th Mar 2025 (Wed) 11,500.00 11,674.00 11,482.00 11,650.00 2,588,111
11th Mar 2025 (Tue) 11,794.00 11,838.00 11,468.00 11,480.00 2,003,098
10th Mar 2025 (Mon) 11,914.00 11,944.00 11,644.00 11,842.00 2,679,806
7th Mar 2025 (Fri) 11,968.00 12,072.00 11,914.00 12,072.00 3,117,389
6th Mar 2025 (Thu) 12,022.00 12,052.00 11,934.00 12,028.00 2,085,808
5th Mar 2025 (Wed) 11,988.00 12,078.00 11,868.00 12,062.00 5,463,303
4th Mar 2025 (Tue) 11,916.00 12,144.00 11,904.00 12,064.00 3,693,572
3rd Mar 2025 (Mon) 11,970.00 12,018.00 11,866.00 11,904.00 3,298,857
28th Feb 2025 (Fri) 11,942.00 12,066.00 11,904.00 11,968.00 4,994,768
See more Astrazeneca price history

Astrazeneca (AZN) Regulatory News

Date Source Headline
21st Mar 2025 10:58 am RNS AZN invests $2.5bn in Beijing R&D & manufacturing
17th Mar 2025 7:10 am RNS Eneboparatide Phase III trial met primary endpoint
17th Mar 2025 7:05 am RNS Imfinzi approved in EU for limited-stage SCLC
17th Mar 2025 7:00 am RNS AstraZeneca to acquire EsoBiotec
12th Mar 2025 6:00 pm RNS Holding(s) in Company
7th Mar 2025 3:00 pm RNS Director/PDMR Shareholding
7th Mar 2025 11:00 am RNS Notice of AGM
7th Mar 2025 7:00 am RNS Imfinzi improved EFS in early-stage gastric cancer
6th Mar 2025 3:00 pm RNS Director/PDMR Shareholding
5th Mar 2025 3:00 pm RNS Director/PDMR Shareholding
See more Astrazeneca regulatory news

Astrazeneca (AZN) Share News

AstraZeneca highlights new Tagrisso data in lung cancer trials

25th Mar 2025 09:04

(Alliance News) - AstraZeneca PLC on Tuesday reported positive new study results for its lung cancer drug Tagrisso, strengthening its position as a "backbone" treatment for patients with EGFR-mutated non-small cell lung cancer, also referred to as NSCLC. Read More

Angle hails successful completion of Eisai contract; approval by Astra

21st Mar 2025 14:25

(Alliance News) - Angle PLC on Friday said the results of an Eisai Co Ltd pilot study supported the capability of the Parsortix system for real-time assessment of breast cancer patient HER2 status. Read More

AstraZeneca to invest USD2.5 billion in new Beijing strategic centre

21st Mar 2025 11:27

(Alliance News) - AstraZeneca PLC on Friday said it will establish a new global strategic research & development centre in Beijing. Read More

IN BRIEF: Hutchmed highlights positive lung cancer test results

20th Mar 2025 14:31

Hutchmed China Ltd - Hong Kong-based biopharmaceutical firm - Results from the Savannah phase 2 trial showed savolitinib plus Tagrisso achieved a clinically meaningful and durable objective response rate in patients with epidermal growth factor receptor mutated non-small cell lung cancer with high levels of MET overexpression and/or amplification, whose disease progressed on treatment with first line Tagrisso. MET refers to abnormal production of a receptor tyrosine kinase, beyond its normal levels, and is associated with tumour growth and progression. Hutchmed will present new and updated data from several studies in Paris at the European Lung Cancer Congress, which will take place between next week Wednesday and March 29. Tagrisso is a drug made by AstraZeneca PLC. Read More

UK dividends calendar - next 7 days

17th Mar 2025 14:22

Read More

See more Astrazeneca news
FTSE 100 Latest
Value8,666.12
Change-23.47

Login to your account

Forgot Password?

Not Registered